{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:13:59Z","timestamp":1790507639477,"version":"4.1.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,12]],"date-time":"2014-07-12T00:00:00Z","timestamp":1405123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.jhep.2014.07.008","type":"journal-article","created":{"date-parts":[[2014,7,15]],"date-time":"2014-07-15T16:20:27Z","timestamp":1405441227000},"page":"1166-1174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"title":["Cyclophilin inhibition as potential therapy for liver diseases"],"prefix":"10.1016","volume":"61","author":[{"given":"Nikolai V.","family":"Naoumov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2014.07.008_b0005","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/gb-2005-6-7-226","article-title":"The cyclophilins","volume":"6","author":"Wang","year":"2005","journal-title":"Genome Biol"},{"key":"10.1016\/j.jhep.2014.07.008_b0010","doi-asserted-by":"crossref","first-page":"e1000439","DOI":"10.1371\/journal.pbio.1000439","article-title":"Structural and biochemical characterization of the human cyclophilin family of peptidyl-prolyl isomerases","volume":"8","author":"Davis","year":"2010","journal-title":"PLoS Biol"},{"key":"10.1016\/j.jhep.2014.07.008_b0015","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1126\/science.6238408","article-title":"Cyclophilin: a specific cytosolic binding protein for cyclosporin A","volume":"226","author":"Handschumacher","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.jhep.2014.07.008_b0020","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/337476a0","article-title":"Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins","volume":"337","author":"Fischer","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2014.07.008_b0025","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/337473a0","article-title":"Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin","volume":"337","author":"Takahashi","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2014.07.008_b0030","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1073\/pnas.90.2.542","article-title":"A cyclophilin-related protein involved in the function of natural killer cells","volume":"90","author":"Anderson","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2014.07.008_b0035","doi-asserted-by":"crossref","first-page":"e888","DOI":"10.1038\/cddis.2013.410","article-title":"Cyclophilin A: a key player for human disease","volume":"4","author":"Nigro","year":"2013","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jhep.2014.07.008_b0040","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.4049\/jimmunol.174.10.6030","article-title":"Cyclophilin A-deficient mice are resistant to immunosuppression by cyclosporine","volume":"174","author":"Colgan","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2014.07.008_b0045","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s12026-011-8263-5","article-title":"Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agents","volume":"52","author":"Gallay","year":"2012","journal-title":"Immunol Res"},{"key":"10.1016\/j.jhep.2014.07.008_b0050","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1515\/hsz-2014-0125","article-title":"Functional aspects of extracellular cyclophilins","volume":"395","author":"Hoffmann","year":"2014","journal-title":"Biol Chem"},{"key":"10.1016\/j.jhep.2014.07.008_b0055","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S0021-9258(17)35315-2","article-title":"Cyclosporin A slows collagen triple-helix formation in vivo: indirect evidence for a physiologic role of peptidyl-prolyl cis-trans-isomerase","volume":"266","author":"Steinmann","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2014.07.008_b0060","doi-asserted-by":"crossref","first-page":"14835","DOI":"10.1016\/S0021-9258(18)98546-7","article-title":"Cyclosporin A inhibits an initial step in folding of transferrin within the endoplasmic reticulum","volume":"266","author":"Lodish","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2014.07.008_b0065","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1074\/jbc.M704934200","article-title":"Cyclophilin A is required for CXCR4-mediated nuclear export of heterogeneous nuclear ribonucleoprotein A2, activation and nuclear translocation of ERK1\/2, and chemotactic cell migration","volume":"283","author":"Pan","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2014.07.008_b0070","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1074\/jbc.M412851200","article-title":"Regulation of CD147 cell surface expression: involvement of the proline residue in the CD147 transmembrane domain","volume":"280","author":"Yurchenko","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2014.07.008_b0075","doi-asserted-by":"crossref","first-page":"37798","DOI":"10.1074\/jbc.M204786200","article-title":"Phosphorylation-dependent interaction of the asialoglycoprotein receptor with molecular chaperones","volume":"277","author":"Huang","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2014.07.008_b0080","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1073\/pnas.042529199","article-title":"Regulation of the tyrosine kinase Itk by the peptidyl-prolyl isomerase cyclophilin A","volume":"99","author":"Brazin","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2014.07.008_b0085","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1161\/CIRCULATIONAHA.107.756106","article-title":"Cyclophilin A mediates vascular remodeling by promoting inflammation and vascular smooth muscle cell proliferation","volume":"117","author":"Satoh","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jhep.2014.07.008_b0090","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.clim.2005.05.004","article-title":"Cyclophilin A may contribute to the inflammatory processes in rheumatoid arthritis through induction of matrix degrading enzymes and inflammatory cytokines from macrophages","volume":"116","author":"Kim","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jhep.2014.07.008_b0095","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/rheumatology\/ken225","article-title":"Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes\/macrophages via CD147 signalling pathway in rheumatoid arthritis","volume":"47","author":"Yang","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jhep.2014.07.008_b0100","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s10875-009-9329-1","article-title":"Contribution of cyclophilin A to the regulation of inflammatory processes in rheumatoid arthritis","volume":"30","author":"Wang","year":"2010","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jhep.2014.07.008_b0105","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nm.1958","article-title":"Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms","volume":"15","author":"Satoh","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2014.07.008_b0110","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1161\/01.RES.87.9.789","article-title":"Cyclophilin A is a secreted growth factor induced by oxidative stress","volume":"87","author":"Jin","year":"2000","journal-title":"Circ Res"},{"key":"10.1016\/j.jhep.2014.07.008_b0115","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1073\/pnas.89.8.3511","article-title":"Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages","volume":"89","author":"Sherry","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2014.07.008_b0120","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4049\/jimmunol.175.1.517","article-title":"Extracellular cyclophilins contribute to the regulation of inflammatory responses","volume":"175","author":"Arora","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2014.07.008_b0125","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1161\/01.ATV.0000130664.51010.28","article-title":"Cyclophilin A is a proinflammatory cytokine that activates endothelial cells","volume":"24","author":"Jin","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jhep.2014.07.008_b0130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1084\/jem.20101174","article-title":"Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E-deficient mice","volume":"208","author":"Nigro","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.jhep.2014.07.008_b0135","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.bbrc.2007.07.085","article-title":"Cyclophilin A is upregulated in small cell lung cancer and activates ERK1\/2 signal","volume":"361","author":"Yang","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhep.2014.07.008_b0140","doi-asserted-by":"crossref","first-page":"8853","DOI":"10.1158\/0008-5472.CAN-05-1219","article-title":"Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo","volume":"65","author":"Howard","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2014.07.008_b0145","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1073\/pnas.88.5.1903","article-title":"Human cyclophilin B: a second cyclophilin gene encodes a peptidyl-prolyl isomerase with a signal sequence","volume":"88","author":"Price","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2014.07.008_b0150","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1073\/pnas.91.9.3931","article-title":"Cyclophilin B trafficking through the secretory pathway is altered by binding of cyclosporin A","volume":"91","author":"Price","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2014.07.008_b0155","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.2174\/0929867033457160","article-title":"Cyclophilin D as a drug target","volume":"10","author":"Waldmeier","year":"2003","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jhep.2014.07.008_b0160","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1253\/circj.CJ-13-0321","article-title":"Physiologic functions of cyclophilin D and the mitochondrial permeability transition pore","volume":"77","author":"Elrod","year":"2013","journal-title":"Circ J"},{"key":"10.1016\/j.jhep.2014.07.008_b0165","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ceca.2011.04.007","article-title":"Mitochondrial permeability transition in Ca2+-dependent apoptosis and necrosis","volume":"50","author":"Rasola","year":"2011","journal-title":"Cell Calcium"},{"key":"10.1016\/j.jhep.2014.07.008_b0170","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1310050","article-title":"Necroptosis","volume":"370","author":"Linkermann","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.07.008_b0175","doi-asserted-by":"crossref","first-page":"12024","DOI":"10.1073\/pnas.1305538110","article-title":"Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury","volume":"110","author":"Linkermann","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2014.07.008_b0180","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/nature03317","article-title":"Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death","volume":"434","author":"Nakagawa","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2014.07.008_b0185","first-page":"433","article-title":"History of the discovery of cyclosporin and of its early pharmacological development","volume":"114","author":"Borel","year":"2002","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.jhep.2014.07.008_b0190","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cld.2009.05.002","article-title":"Cyclophilin inhibitors","volume":"13","author":"Gallay","year":"2009","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2014.07.008_b0195","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1517\/13543784.2012.658641","article-title":"Update on alisporivir in treatment of viral hepatitis C","volume":"21","author":"Flisiak","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jhep.2014.07.008_b0200","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1021\/bi1003266","article-title":"Structural basis for the non-immunosuppressive character of the cyclosporin A analogue Debio 025","volume":"49","author":"Landrieu","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.jhep.2014.07.008_b0205","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.antiviral.2013.03.020","article-title":"Curing a viral infection by targeting the host: the example of cyclophilin inhibitors","volume":"99","author":"Lin","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2014.07.008_b0210","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1128\/AAC.00660-09","article-title":"SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro","volume":"54","author":"Hopkins","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2014.07.008_b0215","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1016\/j.bmcl.2013.05.101","article-title":"Cyclophilin inhibitors as antiviral agents","volume":"23","author":"Peel","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jhep.2014.07.008_b0220","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1128\/AAC.00919-12","article-title":"Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir","volume":"56","author":"Garcia-Rivera","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2014.07.008_b0225","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1128\/AAC.01627-10","article-title":"Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family","volume":"55","author":"Gregory","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2014.07.008_b0230","doi-asserted-by":"crossref","first-page":"7165","DOI":"10.4049\/jimmunol.166.12.7165","article-title":"Sanglifehrin A, a novel cyclophilin-binding compound showing immunosuppressive activity with a new mechanism of action","volume":"166","author":"Zenke","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2014.07.008_b0235","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1021\/ja021327y","article-title":"Sanglifehrin-cyclophilin interaction: degradation work, synthetic macrocyclic analogues, X-ray crystal structure, and binding data","volume":"125","author":"Sedrani","year":"2003","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.jhep.2014.07.008_b0240","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.virol.2009.10.043","article-title":"Multiple cyclophilins involved in different cellular pathways mediate HCV replication","volume":"397","author":"Gaither","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.jhep.2014.07.008_b0245","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.molcel.2005.05.014","article-title":"Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase","volume":"19","author":"Watashi","year":"2005","journal-title":"Mol Cell"},{"key":"10.1016\/j.jhep.2014.07.008_b0250","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1128\/AAC.00939-08","article-title":"Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors","volume":"53","author":"Coelmont","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2014.07.008_b0255","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1074\/jbc.M809244200","article-title":"Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis\/trans isomerase activity of cyclophilins A and B","volume":"284","author":"Hanoulle","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2014.07.008_b0260","doi-asserted-by":"crossref","first-page":"6554","DOI":"10.1128\/JVI.02550-08","article-title":"A critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the HCV replication complex","volume":"83","author":"Liu","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2014.07.008_b0265","doi-asserted-by":"crossref","first-page":"16998","DOI":"10.1074\/jbc.M109.007625","article-title":"The isomerase active site of cyclophilin A is critical for hepatitis C virus replication","volume":"284","author":"Chatterji","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2014.07.008_b0270","doi-asserted-by":"crossref","first-page":"e1000546","DOI":"10.1371\/journal.ppat.1000546","article-title":"Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics","volume":"5","author":"Kaul","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jhep.2014.07.008_b0275","doi-asserted-by":"crossref","first-page":"e13687","DOI":"10.1371\/journal.pone.0013687","article-title":"DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A","volume":"5","author":"Coelmont","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2014.07.008_b0280","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature12427","article-title":"Completion of the entire hepatitis C virus life cycle in genetically humanized mice","volume":"501","author":"Dorner","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2014.07.008_b0285","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jhep.2010.01.041","article-title":"HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors","volume":"53","author":"Chatterji","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.07.008_b0290","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/DDDT.S30946","article-title":"Profile of alisporivir and its potential in the treatment of hepatitis C","volume":"7","author":"Gallay","year":"2013","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.jhep.2014.07.008_b0295","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1128\/AAC.00693-12","article-title":"The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes","volume":"56","author":"Hopkins","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2014.07.008_b0300","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1128\/AAC.00016-14","article-title":"The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance","volume":"58","author":"Chatterji","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2014.07.008_b0305","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/hep.23281","article-title":"Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A","volume":"50","author":"Ciesek","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.008_b0310","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1053\/j.gastro.2014.01.055","article-title":"Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation","volume":"146","author":"Madan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.07.008_b0315","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.antiviral.2011.01.003","article-title":"Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14days of therapy","volume":"89","author":"Lawitz","year":"2011","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2014.07.008_b0320","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jhep.2012.02.024","article-title":"The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection","volume":"57","author":"Hopkins","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.07.008_b0325","first-page":"234A","article-title":"Short duration treatment with SCY-635 restores sensitivity to Peg-IFN\/RBV in difficult to treat, IL28B TT\/CT, HCV Genotype 1 patients","volume":"56","author":"Muir","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.008_b0330","doi-asserted-by":"crossref","first-page":"S336","DOI":"10.1016\/S0168-8278(13)60823-5","article-title":"Interferon (IFN)-free alisporivir (ALV) has a better overall safety profile compared to IFN-containing treatment: a pooled analysis of the ALV development program","volume":"58","author":"Griffel","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.07.008_b0335","doi-asserted-by":"crossref","first-page":"S572","DOI":"10.1016\/S0168-8278(13)61420-8","article-title":"Alisporivir (ALV) plus Peg-Interferon\/Ribavirin (PR) achieves high SVR12 rates among null responders, IL28BCT\/TT and cirrhotic HCVG1 patients (FUNDAMENTAL study)","volume":"58","author":"Buti","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.07.008_b0340","first-page":"309A","article-title":"Alisporivir plus ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (FN)-free or IFN-add-on regimen in treatment-na\u00efve patients with GT2 or GT3: final results of the VITAL-1 study","volume":"56","author":"Pawlotsky","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.008_b0345","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.21679","article-title":"Hepatitis C virus protein expression causes calcium-mediated mitochondrial bioenergetic dysfunction and nitro-oxidative stress","volume":"46","author":"Piccoli","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.008_b0350","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.25514","article-title":"The cyclophilin inhibitor alisporivir prevents hepatitis C virus-mediated mitochondrial dysfunction","volume":"55","author":"Quarato","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.008_b0355","doi-asserted-by":"crossref","first-page":"7713","DOI":"10.1128\/JVI.77.14.7713-7719.2003","article-title":"Activation and inhibition of cellular calcium and tyrosine kinase signaling pathways identify targets of the HBx protein involved in hepatitis B virus replication","volume":"77","author":"Bouchard","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2014.07.008_b0360","doi-asserted-by":"crossref","first-page":"S437","DOI":"10.1016\/S0168-8278(11)61106-9","article-title":"Characterisation of antiviral activities of DEB025 (Alisporivir) and NIM811 on Hepatitis B virus (HBV) replication and HBsAg secretion in vitro","volume":"54","author":"Chokshi","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.07.008_b0365","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1016\/S0168-8278(12)60519-4","article-title":"Alisporivir-induced inhibition of cellular cyclophilins disrupts hepatitis B virus (HBV) replication in vitro and is synergistic in combination with direct antiviral targeted HBV-DNA polymerase","volume":"56","author":"Phillips","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.07.008_b0370","doi-asserted-by":"crossref","first-page":"S423","DOI":"10.1016\/S0168-8278(14)61204-6","article-title":"NVP018, A cyclophilin inhibitor for treatment of chronic HBV infection","volume":"60","author":"Nilsson","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.07.008_b0375","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1128\/JVI.02555-09","article-title":"Hepatitis B virus (HBV) surface antigen interacts with and promotes cyclophilin a secretion: possible link to pathogenesis of HBV infection","volume":"84","author":"Tian","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2014.07.008_b0380","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"10.1016\/j.jhep.2014.07.008_b0385","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jhep.2013.11.022","article-title":"Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor","volume":"60","author":"Nkongolo","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.07.008_b0390","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/hep.26982","article-title":"Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)","volume":"59","author":"Watashi","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.008_b0395","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMra1012478","article-title":"Monogenic mitochondrial disorders","volume":"366","author":"Koopman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.07.008_b0400","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.24367","article-title":"Mitochondrial calcium regulates rat liver regeneration through the modulation of apoptosis","volume":"54","author":"Guerra","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.008_b0405","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/j.1600-6143.2007.01770.x","article-title":"NIM811, a mitochondrial permeability transition inhibitor, prevents mitochondrial depolarization in small-for-size rat liver grafts","volume":"7","author":"Zhong","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2014.07.008_b0410","doi-asserted-by":"crossref","first-page":"13 pages","DOI":"10.1155\/2012\/270372","article-title":"Small-for-size liver transplantation increases pulmonary injury in rats: prevention by NIM811","volume":"2012","author":"Liu","year":"2012","journal-title":"HPB Surg"},{"key":"10.1016\/j.jhep.2014.07.008_b0415","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jhep.2005.03.004","article-title":"NASH: a mitochondrial disease","volume":"42","author":"Pessayre","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.07.008_b0420","doi-asserted-by":"crossref","first-page":"7302","DOI":"10.1021\/jm4007577","article-title":"Anti-inflammatory effects of extracellular cyclosporines are exclusively mediated by CD147","volume":"56","author":"Malesevic","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.jhep.2014.07.008_b0425","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.yjmcc.2012.03.004","article-title":"Cyclophilin A affects inflammation, virus elimination and myocardial fibrosis in coxsackievirus B3-induced myocarditis","volume":"53","author":"Seizer","year":"2012","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.jhep.2014.07.008_b0430","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1440-1746.2010.06406.x","article-title":"N-methyl-4-isoleucine cyclosporine attenuates CCl4-induced liver fibrosis in rats by interacting with cyclophilin B and D","volume":"26","author":"Wang","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2014.07.008_b0435","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/ajt.12620","article-title":"REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C","volume":"14","author":"Levy","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2014.07.008_b0440","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.lfs.2011.01.025","article-title":"Current issues with acetaminophen hepatotoxicity \u2013 A clinically relevant model to test the efficacy of natural products","volume":"88","author":"Jaeschke","year":"2011","journal-title":"Life Sci"},{"key":"10.1016\/j.jhep.2014.07.008_b0445","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1023\/A:1020026923038","article-title":"Mitochondrial permeability transition as a novel principle of hepatorenal toxicity in vivo","volume":"7","author":"Haouzi","year":"2002","journal-title":"Apoptosis"},{"key":"10.1016\/j.jhep.2014.07.008_b0450","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/hep.20437","article-title":"Mitochondrial permeability transition in acetaminophen-induced necrosis and apoptosis of cultured mouse hepatocytes","volume":"40","author":"Kon","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.008_b0455","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jhep.2004.09.015","article-title":"Involvement of mitochondrial permeability transition in acetaminophen-induced liver injury in mice","volume":"42","author":"Masubuchi","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.07.008_b0460","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/hep.24464","article-title":"Acetaminophen overdose-induced liver injury in mice is mediated by peroxynitrite independently of the cyclophilin D-regulated permeability transition","volume":"54","author":"LoGuidice","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.008_b0465","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3109\/10715762.2010.520319","article-title":"Cyclophilin D deficiency protects against acetaminophen-induced oxidant stress and liver injury","volume":"45","author":"Ramachandran","year":"2011","journal-title":"Free Radic Res"},{"key":"10.1016\/j.jhep.2014.07.008_b0470","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.4049\/jimmunol.1100165","article-title":"Cyclophilin A is a damage-associated molecular pattern molecule that mediates acetaminophen-induced liver injury","volume":"187","author":"Dear","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2014.07.008_b0475","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1006\/bbrc.2002.6547","article-title":"Proteome analysis of hepatocellular carcinoma","volume":"291","author":"Lim","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhep.2014.07.008_b0480","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4196\/kjpp.2013.17.5.375","article-title":"Cyclophilin A as a new therapeutic target for hepatitis C virus-induced hepatocellular carcinoma","volume":"17","author":"Lee","year":"2013","journal-title":"Korean J Physiol Pharmacol"},{"key":"10.1016\/j.jhep.2014.07.008_b0485","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s12272-010-0914-x","article-title":"Novel combinational treatment of cisplatin with cyclophilin A inhibitors in human hepatocellular carcinomas","volume":"33","author":"Lee","year":"2010","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.jhep.2014.07.008_b0490","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/hep.24539","article-title":"Role of cyclophilin B in tumorigenesis and cisplatin resistance in hepatocellular carcinoma in humans","volume":"54","author":"Kim","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.008_b0495","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11010-011-0909-z","article-title":"Cyclophilin A promotes human hepatocellular carcinoma cell metastasis via regulation of MMP3 and MMP9","volume":"357","author":"Zhang","year":"2011","journal-title":"Mol Cell Biochem"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827814004772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827814004772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:32:50Z","timestamp":1649637170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827814004772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":99,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0168827814004772"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2014.07.008","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclophilin inhibition as potential therapy for liver diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2014.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}